National Institute of Mental Health; Notice of Closed Meetings, 12008-12009 [2021-04071]
Download as PDF
<![CDATA[
12008
Federal Register / Vol. 86, No. 38 / Monday, March 1, 2021 / Notices
Competitive Advantages
• This invention addresses an urgent
need to protect against permanent
hearing loss resulting from therapies
with commonly used but ototoxic drugs,
including cisplatin.
• Statins are already extensively used
therapeutically to lower blood
cholesterol and have well understood
drug profiles, making them ideal
candidates for repurposing.
Development Stage: An observational
clinical trial (NCT03225157) in patients
with head and neck cancers has been
completed.
Inventors: Lisa Lynn Cunningham
(NIDCD), Nicole C. Schmitt (NIDCD),
and Katharine Ann Fernandez (NIDCD).
Publications: J Clin Invest.
2021;131(1):e142616.
Intellectual Property: HHS Reference
No. E–029–2020—PCT/US21/14918
filed January 25, 2021; U.S. Patent
Application No. 62/966,794 filed
January 28, 2020.
Licensing Contact: Brian W. Bailey,
Ph.D.; 301–594–4094; bbailey@
mail.nih.gov.
Bruce D. Goldstein,
Director, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and
Development, National Institutes of Health.
[FR Doc. 2021–04069 Filed 2–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Heart, Lung, and
Blood Institute (NHLBI), National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of sublicensable
patent licenses to Simon Fraser
University (‘‘Simon Fraser’’), a nonprofit university located in British
Columbia, Canada, and Le Centre
National de la Recherche Scientifique
(‘‘CNRS’’), a public scientific and
technological establishment located in
France, its rights to the inventions and
patents listed in the SUPPLEMENTARY
INFORMATION section of this notice.
DATES: Only written comments and/or
applications for a license which are
received by the NHLBI Office of
Technology Transfer and Development
on or before March 16, 2021 will be
considered.
SUMMARY:
VerDate Sep<11>2014
18:48 Feb 26, 2021
Jkt 253001
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Brian W. Bailey, Ph.D.,
Senior Technology Transfer Manager,
NHLBI Office of Technology Transfer
and Development, 31 Center Drive, Rm.
4A29, MSC 2479, Bethesda, MD 20892–
2479 (for business mail), Telephone
(301) 594–4094; Email: bbailey@
mail.nih.gov.
ADDRESSES:
The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to Stanford: United States
Provisional Patent Application No. 62/
489,346 filed April 24, 2017 and
entitled ‘‘FLUORIGEN–BINDING RNA
APTAMERS’’ [HHS Reference No. E–
152–2018/0–US–01].
The patent rights in these inventions
have been assigned to the Government
of the United States of America, Simon
Fraser, and CNRS. The prospective
patent license will be for the purpose of
consolidating the patent rights to CNRS,
one of the co-owners of said rights, for
commercial development, and the
purpose of consolidating the patent
rights to CNRS and Simon Fraser for
marketing. Consolidation of these coowned rights is intended to expedite
development of the invention,
consistent with the goals of the BayhDole Act codified as 35 U.S.C. 200–212.
The prospective patent license will be
worldwide, exclusive, and may be
limited to those fields of use
commensurate in scope with the patent
rights. It will be sublicensable, and any
sublicenses granted by CNRS or Simon
Fraser will be subject to the provisions
of 37 CFR part 401 and 404.
This invention pertains to certain
RNA aptamers with optimized
fluorescent properties and fluorophore
binding affinities as well as
corresponding heterocyclic
fluorophores. The technology consists of
a suite of fluorescent RNA-fluorophore
complexes within the ‘‘Mango’’ that
have been optimized for live-cell
imaging of RNA molecules without
altering biological function, in a manner
analogous to the way that fluorescently
labeled proteins are used to study
specific protein functions within cells.
As such, this technology can be used as
a powerful tool for live-cell study of
RNA function and activity for research
and diagnostic purposes. The
prospective exclusive patent license
will include terms for the sharing of
royalty income with NHLBI from
commercial sublicenses of the patent
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
rights and may be granted unless within
fifteen (15) days from the date of this
published notice the NHLBI receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license
that are timely filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
patent license. In response to this
Notice, the public may file comments or
objections. Comments and objections,
other than those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5
U.S.C. 552.
Licensing information and copies of
patent applications may be obtained by
emailing Brian W. Bailey, Ph.D.,
bbailey@mail.nih.gov, the indicated
licensing contact at the National Heart,
Lung, and Blood, Office of Technology
Transfer and Development Office of
Technology Transfer, 31 Center Drive,
Room 4A29, MSC2479, Bethesda, MD
20892–2479; telephone: 301–402–5579.
A signed Confidential Disclosure
Agreement may be required to receive
any unpublished information.
Licensing Contact: Brian W. Bailey,
Ph.D.; 301–594–4094; bbailey@
mail.nih.gov.
Bruce D. Goldstein,
Director, Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute, National Institutes of Health.
[FR Doc. 2021–04070 Filed 2–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
E:\FR\FM\01MRN1.SGM
01MRN1
Federal Register / Vol. 86, No. 38 / Monday, March 1, 2021 / Notices
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; Early
Phase Clinical Trials for Psychosocial
Interventions.
Date: March 22, 2021.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Nicholas Gaiano, Ph.D.,
Review Branch Chief, Division of Extramural
Activities, National Institute of Mental
Health, NIH, Neuroscience Center/Room
6150/MSC 9606, 6001 Executive Boulevard,
Bethesda, MD 20892–9606, 301–443–2742,
nick.gaiano@nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; Role
of Myeloid Cells in Brain HIV–1 Reservoirs
(R01, R21).
Date: March 23, 2021.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6101
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: David W. Miller, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6140, MSC 9608,
Bethesda, MD 20892–9608, 301–443–9734,
millerda@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
Suicide Prevention Centers.
Date: March 23, 2021.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Nicholas Gaiano, Ph.D.,
Review Branch Chief, Division of Extramural
Activities, National Institute of Mental
Health, NIH, Neuroscience Center/Room
6150/MSC 9606, 6001 Executive Boulevard,
Bethesda, MD 20892–9606, 301–443–2742,
nick.gaiano@nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
BRAIN Initiative: Tools to Facilitate HighThroughput Microconnectivity Analysis
(R01).
Date: March 25, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
VerDate Sep<11>2014
21:07 Feb 26, 2021
Jkt 253001
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Erin E. Gray, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
6001 Executive Boulevard, NSC 6152B,
Bethesda, MD 20892, 301–402–8152,
erin.gray@nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: February 23, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–04071 Filed 2–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Asthma and Allergic
Diseases Cooperative Research Centers (U19
Clinical Trial Optional).
Date: March 22–23, 2021.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G51,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Thomas F. Conway, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G51, Rockville, MD
20852, 240–507–9685, thomas.conway@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
12009
Dated: February 22, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–04176 Filed 2–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs using Urine or Oral Fluid
(Mandatory Guidelines).
FOR FURTHER INFORMATION CONTACT:
Anastasia Donovan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
2600 (voice); Anastasia.Donovan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: In
accordance with Section 9.19 of the
Mandatory Guidelines, a notice listing
all currently HHS-certified laboratories
and IITFs is published in the Federal
Register during the first week of each
month. If any laboratory or IITF
certification is suspended or revoked,
the laboratory or IITF will be omitted
from subsequent lists until such time as
it is restored to full certification under
the Mandatory Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/resources/drug-testing/
certified-lab-list.
The Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITFs)
currently certified to meet the standards
of the Mandatory Guidelines for Federal
SUMMARY:
E:\FR\FM\01MRN1.SGM
01MRN1
]]>Agencies
[Federal Register Volume 86, Number 38 (Monday, March 1, 2021)]
[Notices]
[Pages 12008-12009]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-04071]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and
[[Page 12009]]
the discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; Early Phase Clinical Trials for Psychosocial
Interventions.
Date: March 22, 2021.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Nicholas Gaiano, Ph.D., Review Branch Chief,
Division of Extramural Activities, National Institute of Mental
Health, NIH, Neuroscience Center/Room 6150/MSC 9606, 6001 Executive
Boulevard, Bethesda, MD 20892-9606, 301-443-2742,
[email protected].
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; Role of Myeloid Cells in Brain HIV-1 Reservoirs
(R01, R21).
Date: March 23, 2021.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6101 Executive Boulevard,
Rockville, MD 20852 (Telephone Conference Call).
Contact Person: David W. Miller, Ph.D., Scientific Review
Officer, Division of Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room
6140, MSC 9608, Bethesda, MD 20892-9608, 301-443-9734,
[email protected].
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; Suicide Prevention Centers.
Date: March 23, 2021.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Nicholas Gaiano, Ph.D., Review Branch Chief,
Division of Extramural Activities, National Institute of Mental
Health, NIH, Neuroscience Center/Room 6150/MSC 9606, 6001 Executive
Boulevard, Bethesda, MD 20892-9606, 301-443-2742,
[email protected].
Name of Committee: National Institute of Mental Health Special
Emphasis Panel; BRAIN Initiative: Tools to Facilitate High-
Throughput Microconnectivity Analysis (R01).
Date: March 25, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Erin E. Gray, Ph.D., Scientific Review Officer,
Division of Extramural Activities, National Institute of Mental
Health, National Institutes of Health, 6001 Executive Boulevard, NSC
6152B, Bethesda, MD 20892, 301-402-8152, [email protected].
(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental
Health Research Grants, National Institutes of Health, HHS)
Dated: February 23, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-04071 Filed 2-26-21; 8:45 am]
BILLING CODE 4140-01-P
